小剂量尿激酶与巴曲酶交替注射治疗短暂性脑缺血发作的临床研究

Clinical Study of Alternate Injection of Low Dose Urokinase and Batroxobin in the Treatment of Transient Ischemic Attack

目的探究短暂性脑缺血发作患者行小剂量尿激酶与巴曲酶交替注射后的临床效果。方法在2017年6月至2018年4月,选取我科室收治的110例TIA患者作为研究对象,随机分为对照组和观察组,对照组行我科室常规治疗,观察组行尿激酶和巴曲酶交替注射,探究治疗效果。结果治愈率、复发率、一年内发生脑梗塞比率、致残及致死率、并发症占比、平均住院日、平均治疗费用上,观察组均优于对照组,差异显著(P<0.05)。结论 TIA患者选择小剂量尿激酶与巴曲酶行交替注射,复发率、致死致残率相对更低,平均住院日缩短,医疗费用和医疗资源均节约,临床值得推广。

Objective To explore the clinical effect of alternate injection of low dose Urokinase and Batroxobin in patients with transient ischemic attack.Methods From June 2017 to April 2018,110 TIA patients were randomly divided into control group and observation group.The control group received routine treatment in our department,while the observation group received alternate injection of Urokinase and Batroxobin to explore the therapeutic effect.Results The cure rate,recurrence rate,incidence of cerebral infarction within one year,disability and mortality rate,complications ratio,average hospitalization days and average treatment cost in the observation group were better than those in the control group,with significant difference(P<0.05).Conclusion TIA patients can choose low dose Urokinase and Batroxobin for alternate injection.The recurrence rate,mortality and disability rate are relatively lower,the average length of stay is shortened,medical expenses and medical resources are saved,and it is worth popularizing in clinic.